Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Affiliations

Comment

Siddharth Jain et al. Ann Intern Med. 2020.

. 2020 Dec 1;173(11):947.

doi: 10.7326/L20-1197.

¹ Postgraduate Institute of Medical Education and Research, Chandigarh, India (S.J., A.C., A.S.).

No abstract available

Comment in

Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Charles P, Guillevin L. Charles P, et al. Ann Intern Med. 2020 Dec 1;173(11):948. doi: 10.7326/L20-1199. Ann Intern Med. 2020. PMID: 33253611 No abstract available.

Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial.
Charles P, Perrodeau É, Samson M, Bonnotte B, Néel A, Agard C, Huart A, Karras A, Lifermann F, Godmer P, Cohen P, Hanrotel-Saliou C, Martin-Silva N, Pugnet G, Maurier F, Sibilia J, Carron PL, Gobert P, Meaux-Ruault N, Le Gallou T, Vinzio S, Viallard JF, Hachulla E, Vinter C, Puéchal X, Terrier B, Ravaud P, Mouthon L, Guillevin L; French Vasculitis Study Group. Charles P, et al. Ann Intern Med. 2020 Aug 4;173(3):179-187. doi: 10.7326/M19-3827. Epub 2020 Jun 2. Ann Intern Med. 2020. PMID: 32479166 Clinical Trial.